Is DMAC stock safe? | Glauxie AI

Q: Is DMAC stock safe?

DiaMedica Therapeutics Inc. (DMAC) operates in the Biotechnology industry (Healthcare sector). The company is led by CEO Dietrich John Pauls. DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human... Employees: 35.

Q: What are the risks of investing in DMAC?

Identify key risks of investing in DMAC — debt, competition, volatility, and sector headwinds.

Q: Is DMAC a good long-term investment?

Evaluate DMAC as a long-term investment using fundamental scores, growth metrics, and risk assessment.

Q: How much debt does DMAC have?

Review DMAC total debt, debt-to-equity ratio, interest coverage, and leverage trends.

Is DMAC stock safe?

🦉

DiaMedica Therapeutics Inc. (DMAC)

Company Overview

Sector / IndustryHealthcare / Biotechnology

CEODietrich John Pauls

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate...

Key Executives

Name	Title
Ambarish Shah	Chief Technology Officer
Dietrich John Pauls	President, Chief Executive Officer & Director
Dominic R. Cundari	Chief Commercial Officer
Julie Krop	Chief Medical Officer
Scott Kellen	Chief Financial Officer & Corporate Secretary

Financial Health

Risk Assessment

Weather Score0/100

RegimeN/A

DMAC Profile Financials

What are the risks of investing in DMAC? Is DMAC a good long-term investment? How much debt does DMAC have?